ERBB2 and breast cancer: With respect to HER2, a recent review of the published data on both adjuvant and neoadjuvant chemotherapy concludes that there is insufficient evidence to use HER2 expression as a predictive factor in breast cancer, as many of the reviewed studies present conflicting data (Hamilton and Piccart, 2000).